Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group.

Raetz EA, Loh ML, Devidas M, Maloney K, Mattano LA Jr, Larsen E, Carroll A, Heerema NA, Gastier-Foster JM, Wood B, Borowitz MJ, Winick N, Hunger SP, Carroll WL.

Haematologica. 2019 Apr 19. pii: haematol.2018.215616. doi: 10.3324/haematol.2018.215616. [Epub ahead of print]

2.

Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.

Sharma ND, Nickl CK, Kang H, Ornatowski W, Brown R, Ness SA, Loh ML, Mullighan CG, Winter SS, Hunger SP, Cannon JL, Matlawska-Wasowska K.

Cancer Sci. 2019 Apr 11. doi: 10.1111/cas.14021. [Epub ahead of print]

3.

Genome-wide association study of susceptibility loci for T-cell acute lymphoblastic leukemia in children.

Qian M, Zhao X, Devidas M, Yang W, Gocho Y, Smith C, Gastier-Foster JM, Li Y, Xu H, Zhang S, Jeha S, Zhai X, Sanda T, Winter SS, Dunsmore KP, Raetz EA, Carroll WL, Winick NJ, Rabin KR, Zweidler-Mckay PA, Wood B, Pui CH, Evans WE, Hunger SP, Mullighan CG, Relling MV, Loh ML, Yang JJ.

J Natl Cancer Inst. 2019 Apr 2. pii: djz043. doi: 10.1093/jnci/djz043. [Epub ahead of print]

PMID:
30938820
4.

Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG.

Nat Genet. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1. Epub 2019 Mar 29.

PMID:
30926971
5.

Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML.

Cancer Res. 2019 May 1;79(9):2339-2351. doi: 10.1158/0008-5472.CAN-18-0236. Epub 2019 Mar 12.

PMID:
30862722
6.

No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.

Robinson KM, Yang W, Karol SE, Kornegay N, Jay D, Cheng C, Choi JK, Campana D, Pui CH, Wood B, Borowitz MJ, Gastier-Foster J, Larsen EC, Winick N, Carroll WL, Loh ML, Raetz EA, Hunger SP, Devidas M, Mardis ER, Fulton RS, Relling MV, Jeha S.

Pediatr Blood Cancer. 2019 Jun;66(6):e27681. doi: 10.1002/pbc.27681. Epub 2019 Mar 7.

PMID:
30848065
7.

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):1061-1062. doi: 10.1038/s41375-019-0426-8.

PMID:
30842605
8.

Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

McNeer JL, Devidas M, Dai Y, Carroll AJ, Heerema NA, Gastier-Foster JM, Kahwash SB, Borowitz MJ, Wood BL, Larsen E, Maloney KW, Mattano L, Winick NJ, Schultz KR, Hunger SP, Carroll WL, Loh ML, Raetz EA.

J Clin Oncol. 2019 Apr 1;37(10):780-789. doi: 10.1200/JCO.18.00884. Epub 2019 Feb 11.

PMID:
30742559
9.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

PMID:
30643249
10.

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.

Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL.

Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146. [Epub ahead of print]

PMID:
30626253
11.

Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.

Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA.

Cancer Discov. 2019 Mar;9(3):436-451. doi: 10.1158/2159-8290.CD-18-1005. Epub 2018 Dec 19.

PMID:
30567843
12.

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.

Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, Larsen E, Rabin KR, Zweidler-McKay PA, Borowitz MJ, Wood B, Heerema NA, Carroll AJ, Winick N, Carroll WL, Raetz EA, Loh ML, Hunger SP.

Haematologica. 2019 May;104(5):986-992. doi: 10.3324/haematol.2018.204545. Epub 2018 Dec 13.

13.

Using genomics to define pediatric blood cancers and inform practice.

Rau RE, Loh ML.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):286-300. doi: 10.1182/asheducation-2018.1.286. Review.

PMID:
30504323
14.

Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics.

Qian M, Xu H, Perez-Andreu V, Roberts KG, Zhang H, Yang W, Zhang S, Zhao X, Smith C, Devidas M, Gastier-Foster JM, Raetz E, Larsen E, Burchard EG, Winick N, Bowman WP, Martin PL, Borowitz M, Wood B, Antillon-Klussmann F, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ.

Blood. 2019 Feb 14;133(7):724-729. doi: 10.1182/blood-2018-07-862946. Epub 2018 Dec 3.

PMID:
30510082
15.

Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.

Wu X, Xu G, Li X, Xu W, Li Q, Liu W, Kirby KA, Loh ML, Li J, Sarafianos SG, Qu CK.

J Med Chem. 2019 Feb 14;62(3):1125-1137. doi: 10.1021/acs.jmedchem.8b00513. Epub 2018 Dec 5.

PMID:
30457860
16.

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.

Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A.

J Exp Med. 2018 Dec 3;215(12):3094-3114. doi: 10.1084/jem.20180570. Epub 2018 Nov 7.

PMID:
30404791
17.

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28. Erratum in: Leukemia. 2019 Mar 7;:.

18.

The genetic basis and cell of origin of mixed phenotype acute leukaemia.

Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG.

Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0. Epub 2018 Sep 12.

19.

Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL.

Kang H, Sharma ND, Nickl CK, Devidas M, Loh ML, Hunger SP, Dunsmore KP, Winter SS, Matlawska-Wasowska K.

Biomark Res. 2018 Aug 23;6:27. doi: 10.1186/s40364-018-0141-z. eCollection 2018.

20.

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.

Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2018 Oct 10;36(29):2926-2934. doi: 10.1200/JCO.2018.77.7250. Epub 2018 Aug 23. Erratum in: J Clin Oncol. 2019 Mar 20;37(9):761.

21.

Generation of a human Juvenile myelomonocytic leukemia iPSC line, CHOPi001-A, with a mutation in CBL.

Gagne AL, Maguire JA, Gandre-Babbe S, Chou ST, Tasian SK, Loh ML, Weiss MJ, Gadue P, French DL.

Stem Cell Res. 2018 Aug;31:157-160. doi: 10.1016/j.scr.2018.07.001. Epub 2018 Jul 5.

22.

Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.

Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, Klco JM.

JCI Insight. 2018 Jul 26;3(14). pii: 121086. doi: 10.1172/jci.insight.121086. eCollection 2018 Jul 26.

23.

Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.

Roberts KG, Reshmi SC, Harvey RC, Chen IM, Patel K, Stonerock E, Jenkins H, Dai Y, Valentine M, Gu Z, Zhao Y, Zhang J, Payne-Turner D, Devidas M, Heerema NA, Carroll AJ, Raetz EA, Borowitz MJ, Wood BL, Mattano LA Jr, Maloney KW, Carroll WL, Loh ML, Willman CL, Gastier-Foster JM, Mullighan CG, Hunger SP.

Blood. 2018 Aug 23;132(8):815-824. doi: 10.1182/blood-2018-04-841676. Epub 2018 Jul 11.

PMID:
29997224
24.

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.

Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST.

Leukemia. 2019 Jan;33(1):181-190. doi: 10.1038/s41375-018-0169-y. Epub 2018 Jun 8.

25.

Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP.

J Clin Oncol. 2018 Aug 1;36(22):2306-2314. doi: 10.1200/JCO.2017.76.7228. Epub 2018 May 29.

PMID:
29812996
26.

High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL.

Perez DR, Nickl CK, Waller A, Delgado-Martin C, Woods T, Sharma ND, Hermiston ML, Loh ML, Hunger SP, Winter SS, Chigaev A, Edwards B, Sklar LA, Matlawska-Wasowska K.

SLAS Discov. 2018 Aug;23(7):732-741. doi: 10.1177/2472555218774248. Epub 2018 May 10.

PMID:
29746793
27.

Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

Churchman ML, Qian M, Te Kronnie G, Zhang R, Yang W, Zhang H, Lana T, Tedrick P, Baskin R, Verbist K, Peters JL, Devidas M, Larsen E, Moore IM, Gu Z, Qu C, Yoshihara H, Porter SN, Pruett-Miller SM, Wu G, Raetz E, Martin PL, Bowman WP, Winick N, Mardis E, Fulton R, Stanulla M, Evans WE, Relling MV, Pui CH, Hunger SP, Loh ML, Handgretinger R, Nichols KE, Yang JJ, Mullighan CG.

Cancer Cell. 2018 May 14;33(5):937-948.e8. doi: 10.1016/j.ccell.2018.03.021. Epub 2018 Apr 19.

28.

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.

Burns MA, Liao ZW, Yamagata N, Pouliot GP, Stevenson KE, Neuberg DS, Thorner AR, Ducar M, Silverman EA, Hunger SP, Loh ML, Winter SS, Dunsmore KP, Wood B, Devidas M, Harris MH, Silverman LB, Sallan SE, Gutierrez A.

Leukemia. 2018 Oct;32(10):2126-2137. doi: 10.1038/s41375-018-0097-x. Epub 2018 Mar 20.

29.

Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.

Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB.

Pediatr Blood Cancer. 2018 Jul;65(7):e27062. doi: 10.1002/pbc.27062. Epub 2018 Mar 30.

PMID:
29603593
30.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

31.

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.

Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, Gao Y, Wall D, Mazor T, Olshen AB, Parker JS, Kahwash S, Hirsch B, Raimondi S, Patel N, Skeens M, Cooper T, Mehta PA, Grupp SA, Loh ML.

Pediatr Blood Cancer. 2018 Jul;65(7):e27034. doi: 10.1002/pbc.27034. Epub 2018 Mar 12.

PMID:
29528181
32.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB.

Blood Adv. 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704.

33.

Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).

Gupta S, Devidas M, Loh ML, Raetz EA, Chen S, Wang C, Brown P, Carroll AJ, Heerema NA, Gastier-Foster JM, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA Jr, Winter SS, Winick NJ, Carroll WL, Hunger SP, Borowitz MJ, Wood BL.

Leukemia. 2018 Jun;32(6):1370-1379. doi: 10.1038/s41375-018-0039-7. Epub 2018 Feb 23.

34.

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.

Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sánchez-Martín M, Madubata CJ, Khiabanian H, Yu J, Waanders E, Iacobucci I, Sulis ML, Kato M, Koh K, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Kirschner-Schwabe R, Mullighan CG, Rabadan R, Ferrando AA.

Nature. 2018 Jan 25;553(7689):511-514. doi: 10.1038/nature25186. Epub 2018 Jan 17.

35.

Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT.

Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

36.

TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.

Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, Carroll A, Heerema NA, Zhang H, Moriyama T, Gastier-Foster JM, Xu H, Raetz E, Larsen E, Winick N, Bowman WP, Martin PL, Mardis ER, Fulton R, Zambetti G, Borowitz M, Wood B, Nichols KE, Carroll WL, Pui CH, Mullighan CG, Evans WE, Hunger SP, Relling MV, Loh ML, Yang JJ.

J Clin Oncol. 2018 Feb 20;36(6):591-599. doi: 10.1200/JCO.2017.75.5215. Epub 2018 Jan 4.

37.

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.

Roberts KG, Yang YL, Payne-Turner D, Lin W, Files JK, Dickerson K, Gu Z, Taunton J, Janke LJ, Chen T, Loh ML, Hunger SP, Mullighan CG.

Blood Adv. 2017 Aug 30;1(20):1657-1671. doi: 10.1182/bloodadvances.2017011296. eCollection 2017 Sep 12.

38.

Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, Borowitz MJ, Devidas M, Maloney KW, Larsen E, Winick N, Raetz E, Carroll WL, Hunger SP, Loh ML, Robins H, Kirsch I.

Blood. 2018 Mar 22;131(12):1350-1359. doi: 10.1182/blood-2017-09-806521. Epub 2017 Dec 28.

39.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.

Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, Borowitz M, Wood B, Heerema NA, Carroll AJ, Hilden JM, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

Cancer. 2018 Mar 15;124(6):1150-1159. doi: 10.1002/cncr.31099. Epub 2017 Dec 19.

40.

Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.

Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML.

Nat Commun. 2017 Dec 19;8(1):2127. doi: 10.1038/s41467-017-02178-9.

41.

Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.

Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA Jr, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A.

Leuk Lymphoma. 2018 Jul;59(7):1624-1633. doi: 10.1080/10428194.2017.1397658. Epub 2017 Nov 8.

42.

Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.

Zheng DJ, Lu X, Schore RJ, Balsamo L, Devidas M, Winick NJ, Raetz EA, Loh ML, Carroll WL, Sung L, Hunger SP, Angiolillo AL, Kadan-Lottick NS.

Cancer. 2018 Feb 1;124(3):571-579. doi: 10.1002/cncr.31085. Epub 2017 Nov 7.

43.

Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.

Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26873. Epub 2017 Nov 1.

44.

Reply to I.J. Cohen.

Hardy KK, Embry LM, Kairalla JA, Helian S, Devidas M, Armstrong FD, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N.

J Clin Oncol. 2017 Dec 10;35(35):3989-3991. doi: 10.1200/JCO.2017.75.7252. Epub 2017 Oct 18. No abstract available.

PMID:
29045162
45.

Philadelphia chromosome-like acute lymphoblastic leukemia.

Tasian SK, Loh ML, Hunger SP.

Blood. 2017 Nov 9;130(19):2064-2072. doi: 10.1182/blood-2017-06-743252. Epub 2017 Oct 2. Review.

46.

Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group.

Hardy KK, Embry L, Kairalla JA, Helian S, Devidas M, Armstrong D, Hunger S, Carroll WL, Larsen E, Raetz EA, Loh ML, Yang W, Relling MV, Noll RB, Winick N.

J Clin Oncol. 2017 Aug 10;35(23):2700-2707. doi: 10.1200/JCO.2016.71.7587. Epub 2017 Jul 3.

47.

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.

Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR, McCastlain K, Edmonson M, Pounds SB, Shi L, Zhou X, Ma X, Sioson E, Li Y, Rusch M, Gupta P, Pei D, Cheng C, Smith MA, Auvil JG, Gerhard DS, Relling MV, Winick NJ, Carroll AJ, Heerema NA, Raetz E, Devidas M, Willman CL, Harvey RC, Carroll WL, Dunsmore KP, Winter SS, Wood BL, Sorrentino BP, Downing JR, Loh ML, Hunger SP, Zhang J, Mullighan CG.

Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3.

48.

Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies.

Tran TH, Shah AT, Loh ML.

Clin Cancer Res. 2017 Sep 15;23(18):5329-5338. doi: 10.1158/1078-0432.CCR-16-0115. Epub 2017 Jun 9. Review.

49.

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Erratum in: Blood. 2017 Sep 28;130(13):1602.

50.

Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

Winick N, Devidas M, Chen S, Maloney K, Larsen E, Mattano L, Borowitz MJ, Carroll A, Gastier-Foster JM, Heerema NA, Willman C, Wood B, Loh ML, Raetz E, Hunger SP, Carroll WL.

J Clin Oncol. 2017 Aug 1;35(22):2527-2534. doi: 10.1200/JCO.2016.71.4774. Epub 2017 May 23.

Supplemental Content

Support Center